Skip to main content

Drug Interactions between Hematinic with Folic Acid and sulfisoxazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sulfiSOXAZOLE folic acid

Applies to: sulfisoxazole and Hematinic with Folic Acid (ferrous fumarate/folic acid)

MONITOR: Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.

MANAGEMENT: Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. van Eijk AM, Ouma PO, Williamson J, et al. (2008) "Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria." J Infect Dis, 198, p. 1550-3
  3. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  4. Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
  5. (2017) "Product Information. Folic Acid (folic acid)." Method Pharmaceuticals, LLC
  6. Van Hensbroek MB, Morris-Jones S, Meisner S, et al. (1995) "Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria." Trans R Soc Trop Med Hyg, 89, p. 672-6
  7. Mulenga M, Malunga P, Bennett S. et.al (2006) "Folic acid treatment of Zambian children with moderate to severe malaria anemia." Am J Trop Med Hyg, 74, p. 986-90
  8. Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM (2005) "Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation." Am J Trop Med Hyg, 73, p. 166-70
  9. Ouma P, Parise ME, Hamel MJ, et al. (2006) "A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine." PLoS Clin Trials, 1, e28
  10. Mbaye A, Richardson K, Balajo B, et al. (2006) "Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae." Am J Trop Med Hyg, 74, p. 760-4
  11. Nzila A, Okombo J, Molloy AM (2014) "Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate." J Antimicrob Chemother, 69, p. 323-30
View all 11 references

Switch to consumer interaction data

Drug and food interactions

Moderate

folic acid food

Applies to: Hematinic with Folic Acid (ferrous fumarate/folic acid)

MONITOR: Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics. Excessive alcohol consumption may lead to folate deficiency.

MANAGEMENT: Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  4. Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
  5. (2017) "Product Information. Folic Acid (folic acid)." Method Pharmaceuticals, LLC
View all 5 references

Switch to consumer interaction data

Moderate

ferrous fumarate food

Applies to: Hematinic with Folic Acid (ferrous fumarate/folic acid)

ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.

Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.

MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.

References

  1. "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
  2. (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer